Savara to Host Third Quarter 2018 Financial Results and Business Update Conference Call on November 7, 2018
November 01, 2018 08:00 ET
|
Savara
AUSTIN, Texas, Nov. 01, 2018 (GLOBE NEWSWIRE) -- Savara Inc. (NASDAQ: SVRA), an orphan lung disease company, today announced it will release its third quarter 2018 financial results on Wednesday,...
Savara Completes Enrollment in Pivotal Molgradex Impala Clinical Study for the Treatment of aPAP
October 15, 2018 08:00 ET
|
Savara
Top Line Results Expected in Q2 2019 AUSTIN, Texas, Oct. 15, 2018 (GLOBE NEWSWIRE) -- Savara Inc. (Nasdaq: SVRA), an orphan lung disease company, today announced completion of the target...
Savara Provides Enrollment Update on Molgradex Impala and OPTIMA Clinical Studies and Reaffirms Guidance for Topline Data
September 27, 2018 08:00 ET
|
Savara
AUSTIN, Texas, Sept. 27, 2018 (GLOBE NEWSWIRE) -- Savara Inc. (Nasdaq: SVRA), an orphan lung disease company, today provided patient enrollment updates for its Molgradex pivotal Phase 3 clinical...
Savara Becomes Inaugural Foundation Sponsor of the PAP Foundation
August 27, 2018 08:00 ET
|
Savara
Savara and the PAP Foundation Form Global Partnership Which Will Support and Unite the Community of Individuals Afflicted with Pulmonary Alveolar Proteinosis (PAP) AUSTIN, Texas and LOS ANGELES, Aug....
Savara to Host Second Quarter 2018 Financial Results and Business Update Conference Call on Thursday, August 9, 2018
August 02, 2018 08:00 ET
|
Savara
AUSTIN, Texas, Aug. 02, 2018 (GLOBE NEWSWIRE) -- Savara Inc. (NASDAQ: SVRA), an orphan lung disease company, today announced it will release its second quarter 2018 financial results on Thursday,...
Savara Announces Pricing of Public Offering of Common Stock
July 26, 2018 09:15 ET
|
Savara
AUSTIN, Texas, July 26, 2018 (GLOBE NEWSWIRE) -- Savara Inc. (Nasdaq:SVRA), an orphan lung disease company, today announced the pricing of an underwritten public offering of 4,250,000 shares of its...
Savara Announces Proposed Public Offering of Common Stock
July 25, 2018 16:16 ET
|
Savara
AUSTIN, Texas, July 25, 2018 (GLOBE NEWSWIRE) -- Savara Inc. (Nasdaq:SVRA), an orphan lung disease company, today announced that it intends to offer and sell, subject to market conditions, shares of...
Savara Provides Positive Update on Development and Commercial Preparations of Molgradex, Including Expansion into NTM In CF
July 25, 2018 16:01 ET
|
Savara
Acquires assets of Cardeas and Announces Appointment of A. Bruce Montgomery, M.D., As Strategic Advisor AUSTIN, Texas, July 25, 2018 (GLOBE NEWSWIRE) -- Savara Inc. (Nasdaq:SVRA), an orphan lung...
Savara to Ring Nasdaq Stock Market Opening Bell on July 23rd
July 23, 2018 08:00 ET
|
Savara
AUSTIN, Texas, July 23, 2018 (GLOBE NEWSWIRE) -- Savara Inc. (Nasdaq:SVRA), an orphan lung disease company, announced today that Rob Neville, CEO of Savara, alongside key members of senior...
Savara Joins Russell 3000® Index
June 25, 2018 08:00 ET
|
Savara
AUSTIN, Texas, June 25, 2018 (GLOBE NEWSWIRE) -- Savara Inc. (NASDAQ:SVRA), an orphan lung disease company, announced today that the company has been added to the broad-market Russell 3000 Index. ...